Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.54 |
| ▸ | KDR | P35968 | 10/20 | 0.54 |
| ▸ | LCK | P06239 | 9/20 | 0.54 |
| ▸ | JAK3 | P52333 | 8/20 | 0.54 |
| ▸ | BRAF | P15056 | 7/20 | 0.50 |
| ▸ | TEK | Q02763 | 2/20 | 0.50 |
| ▸ | RAF1 | P04049 | 6/20 | 0.45 |
| ▸ | KRAS | P01116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612763 | 0.88 | LCK (0.61) | MAPK14KDRLCKJAK3BRAF | |
| SCHEMBL30439800 | 0.88 | LCK (0.61) | MAPK14KDRLCKJAK3BRAF | |
| SCHEMBL26165537 | 0.85 | ABL1 (0.56) | ABL1MAPK14KDRLCKJAK3 | |
| SCHEMBL5498444 | 0.84 | KDR (0.56) | MAPK14KDRLCKJAK3BRAF | |
| SCHEMBL5498060 | 0.84 | MAPK14 (0.58) | ABL1MAPK14KDRLCKJAK3 | |
| SCHEMBL5488786 | 0.83 | LCK (0.65) | ABL1MAPK14KDRLCKJAK3 | |
| SCHEMBL5502234 | 0.83 | LCK (0.67) | ABL1MAPK14KDRLCKJAK3 | |
| SCHEMBL5489142 | 0.82 | LCK (0.79) | ABL1MAPK14KDRLCKJAK3 | |
| SCHEMBL5504366 | 0.82 | MAPK14 (0.52) | MAPK14KDRLCKJAK3BRAF | |
| SCHEMBL5503952 | 0.82 | KDR (0.53) | ABL1MAPK14KDRLCKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | ABL1 8/4885MAPK14 537/4885KDR 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.